The efficacy of using modern antiseptic drugs in ointment form in the treatment of pyoderma and secondarily infected dermatoses

Abstract

BACKGROUND: Pyoderma is one of the most common diseases of the skin and its derivatives. Traditionally, topical antibacterial drugs are used as first-line drugs, but the growth of antibiotic resistance limits their use, and therefore the search for new promising forms of antiseptic drugs remains an urgent task. An antiseptic agent must have a wide antimicrobial spectrum, not irritate the skin and mucous membranes, and remain active for a long time; the antiseptic benzyldimethyl-myristoylamino-propylammonium ointment meets all these requirements. AIM: to evaluate the efficacy and safety of 0.5% benzyldimethyl-myristoylamino-propylammonium ointment in the treatment of pyoderma and secondarily infected dermatoses. MATERIALS AND METHODS: We followed 36 patients with identified polyresistance to topical antibacterial drugs aged 18 to 63 year. 1st group consisted of 22 patients with clinical forms of superficial pyoderma: superficial folliculitis ― 8 (36.4%) cases, sycosis vulgaris ― 4 (18.2%), impetigo vulgaris ― 4 (18.2%), dry streptoderma ― 3 (13.6%), paronychia ― 3 (13.6%). The 2nd cohort included 14 human test subjects with secondarily infected dermatosis: nummular eczema ― 6 cases (42.8%), atopic dermatitis ― 5 (35.8%), secondarily infected contact allergic dermatitis ― 3 (21.4%). RESULTS: As a result of monotherapy with 0.5% benzyldimethyl-myristoylamino-propylammonium ointment in the pyoderma group, clinical recovery (with DIDS=0) was observed in 91.7% of the subjects. The most common dermoscopic pattern was a necrotic rod, the final one was a light red background. Comprehensive treatment of secondarily infected dermatosis in patients of group II, a clinical cure was stated in 71.4% of cases, which is associated with the predominance of chronic, recurrent dermatoses in this cohort of the study, it was noted that dermatosis has a moderate effect on their lives. Initially, during dermatoscopy, there were signs of an acute stage of examination (yellow scales/crusts, punctate vessels, hemorrhages), after therapy ― a stationary stage (white scales). CONCLUSION: Miramistin ointment 0.5% has demonstrated high tolerability and efficacy against various forms of superficial pyoderma and secondarily infected dermatosis and can be recommended for effective use in clinical practice.